FDA approves Bayer drug Sunharbo to reduce stroke recurrence
The FDA approved Bayer's Sunharbo, a novel XIa inhibitor, as the first medication in its class to reduce stroke recurrence. In a Phase 3 trial, Sunharbo reduced the risk of secondary stroke by 26% compared to placebo, with 53 patients needing treatment over one year to prevent one recurrence, offering a safer alternative to traditional blood thinners.
Why it matters. Provides a new treatment option that could prevent secondary strokes more safely for patients who cannot tolerate existing blood thinners due bleeding risk, potentially improving stroke outcomes globally.